Research programme: gene therapy - NanoCor Therapeutics

Drug Profile

Research programme: gene therapy - NanoCor Therapeutics

Alternative Names: BNP-CHF; Carfostin; Intracellular genetic protein therapy - NanoCor Therapeutics

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoCor Therapeutics
  • Class Gene therapies
  • Mechanism of Action Protein phosphatase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 26 Sep 2017 Pharmacodynamics data from preclinical studies in Heart failure released by NanoCor Therapeutics
  • 26 Sep 2017 NanoCor Therapeutics plans a phase I trial for Heart failure in 2018
  • 21 Apr 2016 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top